Condition: Malignant Solid Brain Tumors · Glioblastoma (GBM) · Glioblastoma Multiforme (GBM) · Sponsor: Peking University Third Hospital
This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated natural killer (NK) cells in adult patients with malignant solid brain tumors who have failed standard treatment modalities. The primary objective is to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of the combined NK cell therapy. Secondary objectives include preliminary assessment of anti-tumor activity as measured by progression-free survival (PFS), overall survival (OS), objective response rate (ORR) per RANO criteria, and evaluation of the immunological effects of NK cell infusion in the tumor microenvironment and peripheral blood.
This description comes directly from the study's public registry record.
Chenlong YANG, M.D., Ph.D. · (+86)-135-1108-7060 · vik.yang@pku.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Qinhuangdao Runze Hospital | Qinhuangdao, Hebei, China | Not Yet Recruiting |
| Zhengzhou Second Hospital | Zhengzhou, Henan, China | Recruiting |
| Henan Academy of Innovations in Medical Science | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07552233